• Je něco špatně v tomto záznamu ?

Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN

O. Ledder, A. Assa, A. Levine, JC. Escher, L. de Ridder, F. Ruemmele, N. Shah, R. Shaoul, VM. Wolters, A. Rodrigues, HH. Uhlig, C. Posovsky, KL. Kolho, C. Jakobsen, S. Cohen, DS. Shouval, T. de Meij, J. Martin-de-Carpi, L. Richmond, J. Bronsky,...

. 2017 ; 11 (10) : 1230-1237.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024951

Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort. Method: Retrospective review of children [aged 2-18 years] treated with vedolizumab from 19 centres affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was Week 14 corticosteroid-free remission [CFR]. Results: In all, 64 children were included (32 [50%] male, mean age 14.5 ± 2.8 years, with a median follow-up 24 weeks [interquartile range 14-38; range 6-116]); 41 [64%] cases of ulcerative colitis/inflammatory bowel disease unclassified [UC/IBD-U] and 23 [36%] Crohn's disease [CD]. All were previously treated with anti-tumour necrosis factor [TNF] [28% primary failure, 53% secondary failure]. Week 14 CFR was 37% in UC, and 14% in CD [P = 0.06]. CFR by last follow-up was 39% in UC and 24% in CD [p = 0.24]. Ten [17%] children required surgery, six of whom had colectomy for UC. Concomitant immunomodulatory drugs did not affect remission rate [42% vs 35%; p = 0.35 at Week 22]. There were three minor drug-related adverse events. Only 3 of 16 children who underwent endoscopic evaluation had mucosal healing after treatment (19%). Conclusions: Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024951
003      
CZ-PrNML
005      
20180716120200.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjx082 $2 doi
035    __
$a (PubMed)28605483
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ledder, Oren $u Shaare Zedek Medical Center, Jerusalem, Israel. Hebrew University of Jerusalem, Jerusalem, Israel.
245    10
$a Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN / $c O. Ledder, A. Assa, A. Levine, JC. Escher, L. de Ridder, F. Ruemmele, N. Shah, R. Shaoul, VM. Wolters, A. Rodrigues, HH. Uhlig, C. Posovsky, KL. Kolho, C. Jakobsen, S. Cohen, DS. Shouval, T. de Meij, J. Martin-de-Carpi, L. Richmond, J. Bronsky, M. Friedman, D. Turner,
520    9_
$a Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort. Method: Retrospective review of children [aged 2-18 years] treated with vedolizumab from 19 centres affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was Week 14 corticosteroid-free remission [CFR]. Results: In all, 64 children were included (32 [50%] male, mean age 14.5 ± 2.8 years, with a median follow-up 24 weeks [interquartile range 14-38; range 6-116]); 41 [64%] cases of ulcerative colitis/inflammatory bowel disease unclassified [UC/IBD-U] and 23 [36%] Crohn's disease [CD]. All were previously treated with anti-tumour necrosis factor [TNF] [28% primary failure, 53% secondary failure]. Week 14 CFR was 37% in UC, and 14% in CD [P = 0.06]. CFR by last follow-up was 39% in UC and 24% in CD [p = 0.24]. Ten [17%] children required surgery, six of whom had colectomy for UC. Concomitant immunomodulatory drugs did not affect remission rate [42% vs 35%; p = 0.35 at Week 22]. There were three minor drug-related adverse events. Only 3 of 16 children who underwent endoscopic evaluation had mucosal healing after treatment (19%). Conclusions: Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC.
650    _2
$a mladiství $7 D000293
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a Crohnova nemoc $x farmakoterapie $7 D003424
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a idiopatické střevní záněty $x farmakoterapie $7 D015212
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Assa, Amit $u Schneider Medical Center, Petach Tikva, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Levine, Arie $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Wolfson Medical Center, Holon, Israel.
700    1_
$a Escher, Johanna C $u Erasmus Medical Center, Rotterdam, The Netherlands.
700    1_
$a de Ridder, Lissy $u Erasmus Medical Center, Rotterdam, The Netherlands.
700    1_
$a Ruemmele, Frank $u Hopital Necker Enfants Malades, Paris, France.
700    1_
$a Shah, Neil $u Great Ormond Street Hospital, London, UK.
700    1_
$a Shaoul, Ron $u Rambam Medical Center, Haifa, Israel.
700    1_
$a Wolters, Victorien M $u University Medical Center Utrecht, Utrecht, The Netherlands.
700    1_
$a Rodrigues, Astor $u Oxford University Children's Hospital,Oxford, UK.
700    1_
$a Uhlig, Holm H $u Oxford University Children's Hospital, Oxford, UK. Translational Gastroenterology Unit, Oxford University, UK.
700    1_
$a Posovsky, Carsten $u University Medical Center, Ulm, Germany.
700    1_
$a Kolho, Kaija-Leena $u Helsinki University Central Hospital, Helsinki, Finland.
700    1_
$a Jakobsen, Christian $u Hvidovre University Hospital, Copenhagen, Denmark.
700    1_
$a Cohen, Shlomi $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 'Dana-Dwek' Children's Hospital, Tel Aviv, Israel.
700    1_
$a Shouval, Dror S $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel.
700    1_
$a de Meij, Tim $u VU Medical Centre, Amsterdam, The Netherlands.
700    1_
$a Martin-de-Carpi, Javier $u Hospital Sant Joan de Deu, Barcelona, Spain.
700    1_
$a Richmond, Lisa $u Royal Hospital for Sick Children, Glasgow, Uk.
700    1_
$a Bronsky, Jiri $u University Hospital Motol, Prague, Czech Republic.
700    1_
$a Friedman, Mira $u Shaare Zedek Medical Center, Jerusalem, Israel.
700    1_
$a Turner, Dan $u Shaare Zedek Medical Center, Jerusalem, Israel. Hebrew University of Jerusalem, Jerusalem, Israel.
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 11, č. 10 (2017), s. 1230-1237
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28605483 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716120458 $b ABA008
999    __
$a ok $b bmc $g 1317082 $s 1021872
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 11 $c 10 $d 1230-1237 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace